Tumor Markers
Point-of-care rapid testing for tumor markers. OEM/ODM manufacturer.
Overview
Tumor markers are proteins associated with certain cancers, used in screening support and monitoring of high-risk groups.
Diagnostic Markers & Methods
PSA (prostate) · AFP (hepatocellular) · CEA (colorectal) · CA-series.
Testing Window
Not time-critical; used in screening support and serial monitoring.
Interpretation
Elevated tumor markers are not diagnostic of cancer — imaging and confirmatory testing are required; markers also rise in benign conditions.
Confirmatory Testing
Imaging and biopsy; markers are not diagnostic alone.
The Author's Take
Position: Sell tumor markers as monitoring aids, never as standalone cancer tests — the honest framing is the only sustainable one.
- PSA/AFP/CEA rise in benign conditions too; imaging and confirmatory testing are required.
- Overclaiming a cancer-screening use creates regulatory and reputational risk.
- High-risk surveillance and monitoring are the legitimate, defensible use cases.
This is the buyer-advisor view of the technical team — editorial guidance, not a substitute for product IFU or local regulatory requirements.
Frequently Asked Questions
Can a tumor marker rapid test diagnose cancer?
No — PSA, AFP and CEA rise in benign conditions too, and confirmation requires imaging and other testing. They are monitoring/screening-support aids.
What is PSA used for?
Prostate cancer screening support and monitoring; elevated PSA prompts further evaluation (biopsy), but is not cancer-specific.
What is AFP associated with?
Hepatocellular carcinoma (liver cancer) — used in high-risk surveillance and monitoring, alongside imaging.
Products (3)
Need a full Tumor Markers testing panel? Request datasheets, IFU and OEM/ODM options.